Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - hydroxycarbamidum - capsule - hydroxycarbamidum 500 mg, lactosum monohydricum 41 mg, acidum citricum monohydricum, dinatrii phosphas corresp. natrium 6.6 mg, magnesii stearas, matériel de la capsule: gelatina, e 127, e 171, e 172, e 131, pro capsula. - citostatici - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - hydroxycarbamidum - capsule - hydroxycarbamidum 500 mg, lactosum monohydricum 42.2 mg, acido citricum, dinatrii phosphas corrisp. sodio 11.66 mg, magnesio stearas, kapselhülle: gelatina, e-171, e 127, e 132, e 104, per capsula. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

cps cito pharma services gmbh - hydroxycarbamidum - capsule rigide - hydroxycarbamidum 500 mg, acidum citricum, dinatrii phosphas, magnesii stearas, lactosum monohydricum 42.2 mg, kapselhülle: e 132, e 172 (flavum), e 171, e 127, natrii laurilsulfas, gelatina, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula corresp. natrium 11.7 mg. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - hydroxycarbamidum - comprimés filmés sécables - hydroxycarbamidum 100 mg, cellulosum microcristallinum silicificatum, natrii stearylis fumaras, pellicule: copolymerum methacrylatis butylati basicum, pro compresso obducto, natrium 0.02 mg. - prévention des crises vaso-occlusives douloureuses récurrentes y compris celle du syndrome thoracique aigu chez l’adulte, l’adolescent et l'enfant âgé de plus de 2 ans souffrant de drépanocytose symptomatique - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - hydroxycarbamidum - comprimés filmés sécables - hydroxycarbamidum 1000 mg, cellulosum microcristallinum silicificatum, natrii stearylis fumaras, pellicule: copolymerum methacrylatis butylati basicum, pro compresso obducto, natrium 0.21 mg. - prévention des crises vaso-occlusives douloureuses récurrentes y compris celle du syndrome thoracique aigu chez l’adulte, l’adolescent et l'enfant âgé de plus de 2 ans souffrant de drépanocytose symptomatique - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

hikma farmaceutica (portugal) s.a. - idrossicarbamide - idrossicarbamide

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, falce cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teofarma s.r.l. - idrossicarbamide - idrossicarbamide

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

bristol myers squibb s.r.l. - idrossicarbamide - idrossicarbamide

Unione Europea - italiano - EMA (European Medicines Agency)

theravia - idrossicarbamide - anemia, falce cell - agenti antineoplastici - siklos è indicato per la prevenzione della recidiva di doloroso vaso-occlusiva crisi quali sindrome toracica acuta in pazienti adulti e pediatrici pazienti sintomatici affetti da anemia a cellule sindrome.